ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic lupus erythematosus (SLE)"

  • Abstract Number: 1285 • ACR Convergence 2021

    Major Determinants of Prolonged Remission in Systemic Lupus Erythematosus: Retrospective Study over a 41-Year Period

    Goncalo Durao-Carvalho1, Raquel Fernandez2, Bethan Goulden3, Filipa Farinha4 and David Isenberg5, 1Servico de Medicina Interna, Centro Hospitalar do Oeste – Unidade de Caldas da Rainha, Caldas da Rainha, Portugal, Caldas da Rainha, Portugal, 2Servicio de Medicina Interna, Hospital Universitario de Ourense, Ourense, Spain, 3Department of Rheumatology, University College London Hospitals, London, United Kingdom, 4Department of Rheumatology, University College London Hospitals and Centre for Rheumatology, University College London, London, United Kingdom, 5Centre for Rheumatology, University College London, London, United Kingdom

    Background/Purpose: Disease activity is a major determinant of mortality whereas prolonged remission contributes to improving health outcomes in SLE patients (pts). Remission is thus a…
  • Abstract Number: 1302 • ACR Convergence 2021

    Year-3 Observational Follow-up of Belimumab Safety (Mortality and Malignancies) in Patients with SLE Who Completed a Phase 4, 52-Week, Randomized, Double-Blind Placebo-Controlled Safety Study

    Saira Sheikh1, Cheng-Chung Wei2, Dana Tegzova3, William Stohl4, Ricardo Acayaba de Toledo5, Tamara Mucenic6, Mauricio Abello Banfi7, Kathleen Maksimowicz-McKinnon8, Carlos Abud-Mendoza9, Sandra Navarra10, Mercedes Garcia11, Ignacio Garcia-De La Torre12, Regina Kurrasch13, Sofia Fernandes14, Julia Harris15, Saima Muzaffar14, Norma Lynn Fox13, Andrew Liu16, Holly Quasny17 and David Roth13, 1University of North Carolina Thurston Arthritis Research Center, and Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, 2Institute of Medicine, Chung Shan Medical University; Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan (Republic of China), 3Institute of Rheumatology, Prague, Czech Republic, 4University of Southern California Keck School of Medicine, Los Angeles, CA, 5Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, Brazil, 6Hospital Moinhos de Vento, Porto Alegre, Brazil, 7Centro Integral de Reumatología del Caribe, Barranquilla, Colombia, 8Henry Ford Hospital, Wayne State University, Detroit, MI, 9Hospital Central “Dr Ignacio Morones Prieto”, Unidad Regional de Reumatología y Osteoporosis, Hospital Central and Facultad de Medicina de la Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, 10University of Santo Tomas Hospital, Manila, Philippines, 11Hospital Interzonal General de Agudos José de San Martín, La Plata, Argentina, 12Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, 13GlaxoSmithKline, Collegeville, PA, 14GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, 15GlaxoSmithKline, Uxbridge, United Kingdom, 16GlaxoSmithKline, Brentford, United Kingdom, 17GlaxoSmithKline, Research Triangle Park, NC

    Background/Purpose: Belimumab (BEL) is a recombinant IgG1λ monoclonal antibody that is approved for treatment of systemic lupus erythematosus (SLE). Although clinical studies of BEL have…
  • Abstract Number: 1463 • ACR Convergence 2021

    Use of Telemedicine for Follow-up of Lupus Nephritis in the COVID-19 Outbreak: The 6-month Results of a Randomized Controlled Trial

    ho SO1, Evelyn Chow1, Isaac Cheng1, Xerox Lau1, Tena Li1, Cheuk Chun Szeto1 and Lai-Shan Tam2, 1The Chinese University of Hong Kong, Hong Kong, Hong Kong, 2Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China (People's Republic)

    Background/Purpose: Telemedicine (TM) has been widely advocated and used to follow up patients with rheumatic diseases during the COVID-19 outbreak. However, there is no evidence…
  • Abstract Number: 1496 • ACR Convergence 2021

    A Metagenome-wide Association Study Revealed Disease-specific Landscape of the Gut Microbiome of Systemic Lupus Erythematosus in Japanese

    Yoshihiko Tomofuji1, Yuichi Maeda2, Eri Oguro-Igashira2, Toshihiro Kishikawa1, Kenichi Yamamoto1, Kyuto Sonehara1, Daisuke Motooka3, Yuki Matsumoto3, Hidetoshi Matsuoka4, Maiko Yoshimura4, Mayu Yagita2, Takuro Nii2, Shiro Ohshima5, Shota Nakamura3, Hidenori Inohara6, Kiyoshi Takeda7, Atsushi Kumanogoh2 and Yukinori Okada1, 1Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan, 2Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Japan, 3Department of Infection Metagenomics, Research Institute for Microbial Diseases, Osaka University, Suita, Japan, 4Rheumatology and Allergology, NHO Osaka Minami Medical Center, Kawachinagano, Japan, 5Rheumatology and Allergology, NHO Osaka Minami Medical Center, Suita, Japan, 6Department of Otorhinolaryngology - Head and Neck Surgery, Osaka University Graduate School of Medicine, Suita, Japan, 7Laboratory of Immune Regulation, Department of Microbiology and Immunology, Osaka University Graduate School of Medicine, Suita, Japan

    Background/Purpose: Alteration of the gut microbiome has been linked to the pathogenesis of systemic lupus erythematosus (SLE). However, a comprehensive view of the gut microbiome…
  • Abstract Number: 1621 • ACR Convergence 2021

    Self-reported Transition Readiness of Adolescent Patients with Rheumatologic Disease: Do the Parents Agree?

    Christina Ma1, Molly Dushnicky1, Habeba Talaat1, Steffy Thomas1, Karen Beattie1, Tania Cellucci2, Stephanie Garner1, Liane Heale1, Mark Matsos1 and Michelle Batthish1, 1McMaster University, Hamilton, ON, Canada, 2McMaster Children's Hospital, Hamilton, ON, Canada

    Background/Purpose: The transition from pediatric to adult rheumatology care is associated with increased disease activity and morbidity. The parent-child relationship is a significant relationship in…
  • Abstract Number: 1734 • ACR Convergence 2021

    Efavaleukin Alfa, a Novel IL-2 Mutein, Selectively Expands Regulatory T Cells in Patients with SLE: Interim Results of a Phase 1b Multiple Ascending Dose Study

    Nadia Tchao1, Hamid Amouzadeh2, Nandita Sarkar1, Vincent Chow2, Xuguang Hu1, Mark Kroenke2, Hui Wang2, Rong Zhang2, Kevin Gorski1, Richard Furie3, Alan Kivitz4 and Stanley Cohen5, 1Amgen Inc., South San Francisco, CA, 2Amgen Inc., Thousand Oaks, CA, 3Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 4Altoona Center for Clinical Research, Duncansville, PA, 5Metroplex Clinical Research Center, Dallas, TX

    Background/Purpose: Diminished IL-2 as well as both quantitative and qualitative abnormalities in regulatory T cells (Treg) are associated with autoimmune diseases including SLE. Efavaleukin alfa…
  • Abstract Number: 1755 • ACR Convergence 2021

    Increasing Participation of Underrepresented Groups in Lupus Clinical Trials: Insights from Qualitative Interviews with Patients and Physicians

    Saira Sheikh1, Maria Naylor2, Becky Lane2, Jennifer Sacks2, Janine Gaiha-Rohrbach2 and Cherie Butts2, 1University of North Carolina Thurston Arthritis Research Center, and Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, 2Biogen, Cambridge, MA

    Background/Purpose: Systemic lupus erythematosus disproportionately affects Black/African American (AA) and Latino/a populations.1 Challenges to engage and include these populations in clinical trials (CTs) can be…
  • Abstract Number: 1772 • ACR Convergence 2021

    Autologous EBV-specific Cytotoxic T Cells in Systemic Lupus Erythematosus: An Innovative Phase I/IIa Clinical Trial

    Antoine Enfrein1, Beatrice Clemenceau2, Soraya Saiagh3, Céline Bressollette4, Zahir Amoura5, Henri Vie2 and Mohamed Hamidou1, 1Médecine interne, CHU de Nantes, Nantes, France, 2Inserm U1232, Université de Nantes, Nantes, France, 3Unité de Thérapie Cellulaire et Génique, CHU de Nantes, Nantes, France, 4Laboratoire de Virologie, CHU de Nantes, Nantes, France, 5Médecine interne, Hôpital Pitié Salpêtrière, AP-HP, Paris, France

    Background/Purpose: Epstein-Barr Virus (EBV) has been suggested as a potential environmental factor in systemic lupus erythematosus (SLE) onset and disease activity. Here, we report the…
  • Abstract Number: 0133 • ACR Convergence 2021

    Cervical Cancer Screening Rate in Women with Systemic Lupus Erythematosus

    Erica Rosen1 and Megan Krause2, 1University of Kansas, Kansas City, MO, 2University of Kansas, Kansas City, KS

    Background/Purpose: Females with systemic lupus erythematosus have increased rates of cervical cancer especially if on immunosuppressive therapy. The American Cancer Society reports the incidence of…
  • Abstract Number: 0332 • ACR Convergence 2021

    Prevalence of Systemic Lupus Erythematosus in the United States: Updated Population Representative Estimates from the Medical Expenditure Panel Survey (MEPS) 2016-2018

    Michael Pollack1, Sandra Sze-jung Wu1, Eilleen Farrelly2, Shannon Grabich3 and Robert Ortmann4, 1AstraZeneca, Wilmington, DE, 2Xcenda, Carrollton, TX, 3Xcenda, Durham, NC, 4AstraZeneca, Greenwood, IN

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, multi-organ, autoimmune disease whose prevalence in the US has not been recently updated in real-world studies. Prevalence…
  • Abstract Number: 0349 • ACR Convergence 2021

    Performance of the 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Predominantly African American Cohort

    Jessica English1, Dulaney Wilson2, Gary Gilkeson2, Jim Oates2 and Diane Kamen2, 1Medical University of South Carolina, Johns Island, SC, 2Medical University of South Carolina, Charleston, SC

    Background/Purpose: Classification criteria for systemic lupus erythematosus (SLE) were recently published by the European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR) to…
  • Abstract Number: 0534 • ACR Convergence 2021

    Lymphatic Dysfunction in Murine Lupus Photosensitivity

    William Ambler1, Noa Schwartz2, Jin Yeon Shin3, Rahgu Kataru4, Camila Carballo5, Scott Rodeo6, Babak Mehrara4 and Theresa Lu7, 1Division of Pediatric Rheumatology, Department of Rheumatology, Hospital for Special Surgery. HSS Research Institute, Hospital for Special Surgery, New York, NY, 2Department of Medicine, Division of Rheumatology, Albert Einstein College of Medicine, New York, NY, 3Department of Surgery, Division of Plastic and Reconstructive Surgery Memorial Sloan Kettering, New York, NY, 4Department of Surgery, Division of Plastic and Reconstructive Surgery, Memorial Sloan Kettering, New York, NY, 5HSS Research Institute, Hospital for Special Surgery, New York, NY, 6HSS Research Institute, Hospital for Special Surgery; Department of Orthopedics, Hospital for Special Surgery, New York, NY, 7Hospital for Special Surgery, New York, NY

    Background/Purpose: The lymphatic system is composed of vessels which carry fluid, soluble molecules, and cells from peripheral tissue to draining lymph nodes. Photosensitivity, an exaggerated…
  • Abstract Number: 0624 • ACR Convergence 2021

    Validation of a Self-reported Measure of Extent and Reasons for Nonadherence in SLE

    Kai Sun1, Amanda Eudy2, D. Ryan Anderson3, Rebecca Sadun2, Lisa Criscione-Schreiber1, Jayanth Doss2, Jennifer Rogers1, Theresa Coles2, Corrine Volis4 and Megan Clowse5, 1Duke University School of Medicine, Durham, NC, 2Duke University, Durham, NC, 3Duke University Medical Center, Durham, NC, 4University of Wisconsin School of Medicine and Public Health, Madison, WI, 5Duke University, Chapel Hill, NC

    Background/Purpose: Medication nonadherence is common in SLE and leads to increased hospitalizations, morbidity, and mortality. To better recognize nonadherence and address adherence barriers, there is…
  • Abstract Number: 0856 • ACR Convergence 2021

    Identifying COVID-19 Infection Rates and Outcomes in Patients with Systemic Lupus Erythematosus

    Alexander Hall1, Michael Trevisonno1, Elizabeth Murray1, Omoakhe Tisor1, Emily Stanford1, Jacob Gaines1, Noor Anvery1 and Ellen Ginzler2, 1SUNY Downstate Health Sciences University College of Medicine, Brooklyn, NY, 2SUNY Downstate Health Sciences University, Brooklyn, NY

    Background/Purpose: The risk of COVID-19 infection among patients with Systemic Lupus Erythematosus (SLE) is poorly understood. Patients with SLE often take medications which modulate the…
  • Abstract Number: 0873 • ACR Convergence 2021

    Clinical and Serological Characteristics of Latin American Patients with Lupus Enteritis: A Case-Control Study

    Marcela Muñoz-Urbano1, Julian Sanchez-Bautista2, Yeison Santamaria-Alza1, Diana C. Quintero-González3, Andres Ramirez2, Adriana Lucía Vanegas-García4, Gloria M. Vasquez1 and Luis Alonso Gonzalez3, 1Rheumatology section, Universidad de Antioquia, Medellín, Colombia, 2Department of internal medicine, Universidad de Antioquia, Medellín, Colombia, 3Division of rheumatology, Universidad de Antioquia, Medellín, Colombia, 4Division of rheumatology, Universidad de Antioquia – Hospital San Vicente Fundación, Medellín, Colombia

    Background/Purpose: Lupus enteritis (LE) is a potentially life-threatening manifestation of systemic lupus erythematosus (SLE), with an incidence ranging from 8% to 27%. Timely diagnosis is…
  • « Previous Page
  • 1
  • …
  • 120
  • 121
  • 122
  • 123
  • 124
  • …
  • 181
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology